Open-source drug research consortium draws a major new champion

TakedaTakeda Pharmaceutical Company Limited (Takeda) has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster. The SGC is based at the Universities of Toronto, Canada, and Oxford, England.

Takeda's contribution raises the total to $50 million in support of the SGC by six of the world's leading pharmaceutical companies engaged in drug discovery, bolstering this ground-breaking pre-competitive approach to drug research. The addition by Takeda represents a significant increase in industry funding from the previous four years when three drug makers provided $13 million in funds.

The new agreement with SGC, one of the largest ever public-private drug discovery partnerships, increases the profile of more than 200 scientists from academia and industry who make all early-stage research openly available with no patents or restrictions. The SGC's research network helps Takeda promote its drug discovery efforts by accessing new research first hand. The company also can influence the research direction of the SGC network by participating on the SGC Scientific Committee and its Board of Directors.

"This is a strong endorsement of a novel business model, which relies on collaboration to share the risks of early-stage research, and reduce costs of drug discovery so we can get effective new medicines to market faster, and into the hands of physicians and patients sooner," said Aled Edwards, the Canada-based Chief Executive, SGC.

"As a global leader in research, Takeda is dedicated to helping change the way drug discovery is conducted," said Paul Chapman, General Manager, Pharmaceutical Research Division, Takeda. "We are very excited about the opportunity to become a part of the SGC, and firmly believe that important new medicines will be discovered in industry and vital scientific knowledge will be gained in academia through this open innovation."

The SGC identifies and maps the three-dimensional structure of human proteins, which are the targets for drug discovery. Learning about the precise structure of human proteins provides important clues to discover new drugs.

About The Structural Genomics Consortium (SGC)
Located at the Universities of Toronto and Oxford, the not-for-profit organization supports the discovery of new medicines by carrying open access research in structural and chemical biology. More than 200 researchers in academia and in six pharmaceutical companies collaborate within SGC to accomplish these goals. The SGC is also funded by the Canadian Institutes for Health Research, CFI, Genome Canada, the Ontario's MEDI, and the Wellcome Trust.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...